These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35386181)

  • 21. Soluble Guanylate Cyclase Activators and Stimulators in Patients with Heart Failure.
    Liang WL; Liang B
    Curr Cardiol Rep; 2023 Jun; 25(6):607-613. PubMed ID: 37079245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure.
    Sahana U; Wehland M; Simonsen U; Schulz H; Grimm D
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction.
    Nakamura M; Imamura T; Kinugawa K
    J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
    Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B;
    JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction.
    Falco L; Brescia B; Catapano D; Martucci ML; Valente F; Gravino R; Contaldi C; Pacileo G; Masarone D
    J Cardiovasc Dev Dis; 2023 Sep; 10(9):. PubMed ID: 37754817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
    Ruehs H; Klein D; Frei M; Grevel J; Austin R; Becker C; Roessig L; Pieske B; Garmann D; Meyer M
    Clin Pharmacokinet; 2021 Nov; 60(11):1407-1421. PubMed ID: 34086190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble Guanylate Cyclase Stimulators in Heart Failure.
    Kansakar S; Guragain A; Verma D; Sharma P; Dhungana B; Bhattarai B; Yadav S; Gautam N
    Cureus; 2021 Sep; 13(9):e17781. PubMed ID: 34659992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying the patient with heart failure to be treated with vericiguat.
    Escobar Cervantes C; Esteban Fernández A; Recio Mayoral A; Mirabet S; González Costello J; Rubio Gracia J; Núñez Villota J; González Franco Á; Bonilla Palomas JL
    Curr Med Res Opin; 2023 May; 39(5):661-669. PubMed ID: 36897009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES).
    Pieske B; Butler J; Filippatos G; Lam C; Maggioni AP; Ponikowski P; Shah S; Solomon S; Kraigher-Krainer E; Samano ET; Scalise AV; Müller K; Roessig L; Gheorghiade M;
    Eur J Heart Fail; 2014 Sep; 16(9):1026-38. PubMed ID: 25056511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.
    Ullah W; Mukhtar M; Al-Mukhtar A; Saeed R; Boigon M; Haas D; Rame E
    World J Cardiol; 2020 Oct; 12(10):501-512. PubMed ID: 33173569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
    Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.
    Fritsch A; Meyer M; Blaustein RO; Trujillo ME; Kauh E; Roessig L; Boettcher M; Becker C
    Clin Pharmacokinet; 2024 Jun; 63(6):751-771. PubMed ID: 38916717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vericiguat in heart failure: From scientific evidence to clinical practice.
    González-Juanatey JR; Anguita-Sánchez M; Bayes-Genís A; Comín-Colet J; García-Quintana A; Recio-Mayoral A; Zamorano-Gómez JL; Cepeda-Rodrigo JM; Manzano L
    Rev Clin Esp (Barc); 2022; 222(6):359-369. PubMed ID: 35473692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Updates in pharmacotherapy of heart failure with reduced ejection fraction.
    Espinoza C; Alkhateeb H; Siddiqui T
    Ann Transl Med; 2021 Mar; 9(6):516. PubMed ID: 33850913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event.
    Alsumali A; Lautsch D; Liu R; Patel D; Nanji S; Djatche LM
    Adv Ther; 2021 May; 38(5):2631-2643. PubMed ID: 33860924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis.
    Trujillo ME; Arrington L; Patel Y; Passarell J; Wenning L; Blaustein RO; Armstrong PW; Meyer M; Becker C; Gheyas F
    Clin Pharmacol Ther; 2022 Nov; 112(5):1061-1069. PubMed ID: 35841202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vericiguat, organic nitrates, and heart failure in African Americans.
    Ilonze OJ; Guglin M
    Int J Cardiol; 2021 Sep; 338():136-137. PubMed ID: 34157357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF).
    Xia J; Hui N; Tian L; Liang C; Zhang J; Liu J; Wang J; Ren X; Xie X; Wang K
    Biomed Pharmacother; 2022 May; 149():112894. PubMed ID: 35367763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction.
    Abuelazm MT; Attia A; Abdelnabi M; Jafar U; Almaadawy O; Elzeftawy MA; Mahmoud A; Albakri K; Abdelazeem B
    Egypt Heart J; 2024 Jan; 76(1):6. PubMed ID: 38265696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective.
    Alsumali A; Djatche LM; Briggs A; Liu R; Diakite I; Patel D; Wang Y; Lautsch D
    Pharmacoeconomics; 2021 Nov; 39(11):1343-1354. PubMed ID: 34623625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.